1. Most Discussed
  2. Gainers & Losers
  1. Members, Techs apologise for the loss of thread titles, and are currently working on restoring them. They will be back asap. Thank you
PGL $3.64


  1. acouch

    5,582 Posts.

    15th of July 2002

    PI-88 Clinical Trials Update [April-June 2002]

    In April we announced that the first patients have been enrolled in a Phase II trial of PI-88 in multiple myeloma at The Mater Misericordiae Hospital (Newcastle) and the Wesley Clinic Research Centre (Brisbane). This followed on from the enrolment of the first patient in the trial, Maureen Tilders, at the Alfred Hospital in Melbourne (pictured below with Bone Marrow Transplant Unit Clinical Trials Coordinator Nola Kennedy).

    read more

    Milestone in Heparanase Drug Design Program

    Progen has reached a significant milestone in its program to develop novel drugs to inhibit the enzyme heparanase.

    read more

    Contract manufacturing agreement with U.S. Biotech
    International Recognition of Progen’s cGMP Expertise

    In early April we announced a AUD500,000 manufacturing contract with US biotechnology company Lipid Sciences to provide manufacturing and clinical support for their Phase I Clinical Trial.

    read more

    Progen platform technology development moving forward

    Progen has submitted a second provisional specification with the Australian Patent Office titled ‘The process for synthesising C-glycosides’. The inventors, Doctors Martin Banwell and David Armitt from the Australian National University (ANU), were funded through a Progen collaboration with ANU.

    read more

    On the road .....

    In May, Progen’s VP of Business Development, Dr Peter Devine (pictured below with other delegates), attended the 5th Australia-Japan Symposium on Drug Design and Development in Japan. Dr Devine delivered two presentations at the meeting, and participated in a business partnering session with potential Japanese alliance partners. Other highlights of the trip included a networking reception at the Australian Consulate General’s home in Osaka, where many key Japanese pharmaceutical representatives attended. An article on Progen appeared in Japan’s leading economic and business newspaper (Nihon Kensai Shimbun) that has a circulation of over 3 million.

    read more

    Progen not affected by R&D Start Grant suspension

    The Federal Government’s suspension of the Start Grant scheme following a $40 million blow-out this financial year will not affect Progen’s $3 million grant awarded late 2001.

    read more

    The Progen Investigator
    Simplifying the Science

    The Progen Investigator is designed to answer your questions about technical related issues. Below are some answers to common questions about PI-88, our lead drug candidate. Please feel free to submit your inquiries to [email protected]

    read more

    For Further Information

    PROGEN e-NEWS aims to keep you informed of significant developments and milestones achieved by Progen Industries Limited. For information about any topics in this newsletter, please contact:

    read more

    have a good evening

Before making any financial decisions based on what you read, always consult an advisor or expert.

The HotCopper website is operated by Report Card Pty Ltd. Any information posted on the website has been prepared without taking into account your objectives, financial situation or needs and as such, you should before acting on the information or advice, consider the appropriateness of the information or advice in relation to your objectives, financial situation or needs. Please be aware that any information posted on this site should not be considered to be financial product advice.

From time to time comments aimed at manipulating other investors may appear on these forums. Posters may post overly optimistic or pessimistic comments on particular stocks, in an attempt to influence other investors. It is not possible for management to moderate all posts so some misleading and inaccurate posts may still appear on these forums. If you do have serious concerns with a post or posts you should report a Terms of Use Violation (TOU) on the link above. Unless specifically stated persons posting on this site are NOT investment advisors and do NOT hold the necessary licence, or have any formal training, to give investment advice.


Thank you for visiting HotCopper

We have detected that you are running ad blocking software.

HotCopper relies on revenue generated from advertisers. Kindly disable your ad blocking software to return to the HotCopper website.

I understand, I have disabled my ad blocker. Let me in!

Need help? Click here for support.